Pharmacological Inhibition of 5α-Reductase in Androgenetic Alopecia: A Comparative Narrative Review of Finasteride and Dutasteride, with Attention to Responder Heterogeneity and Female Pattern Hair Loss

The conversation is about managing allopregnanolone deficiency caused by 5-alpha-reductase inhibitors like finasteride or dutasteride. Specific treatments discussed for hair loss include Minoxidil, finasteride, and RU58841.

Dutasteride and finasteride have similar risks of sexual dysfunction for treating androgenetic alopecia. Users experience varying side effects, indicating individual differences in drug reactions.

Dutasteride at 2.5 mg/day reduces scalp DHT by 80%, while 0.5 mg/day reduces it by 50%, with minimal difference in side effects. Users often combine it with finasteride, RU58841, and minoxidil for better hair loss management, though side effects like dry skin and pimples are noted.

Androgenetic alopecia is affected by scalp DHT levels, not sensitivity, with treatments like finasteride and dutasteride aiming to optimize these levels. Personalized DHT management is crucial for effective hair growth.

The conversation discusses that dutasteride may be more effective than finasteride for frontal hair loss due to higher 5ar Type 1 enzyme activity in that area. Some users question the validity of this information, while others confirm it with additional sources.

Higher doses of dutasteride reduce scalp DHT more effectively than finasteride, but have diminishing returns after 3mg daily and may cause more side effects. Combining dutasteride with topical minoxidil can enhance results, but using both finasteride and dutasteride together is unnecessary.